# DESCRIPTION

## FIELD OF THE INVENTION

- introduce soluble FGF decoy polypeptides

## BACKGROUND OF THE INVENTION

- describe FGFR3 and skeletal growth retardation disorders

## SUMMARY OF THE INVENTION

- introduce sFGFR3 decoy polypeptides
- describe fusion protein sFGF decoy polypeptide
- specify amino acid sequences
- describe aggrecan-binding protein or fragment
- specify Fc region
- introduce second aspect of invention
- describe sFGF decoy polypeptide
- specify amino acid sequences
- describe fusion polypeptide or sFGF decoy polypeptide
- introduce third aspect of invention
- describe nucleic acid encoding fusion protein or sFGF decoy polypeptide
- introduce fourth to seventh aspects of invention

## Definitions

- define scope of invention
- establish terminology
- introduce aggrecan protein
- define aggrecan-binding protein
- explain binding protein concept
- describe biological activity of parent polypeptide
- define cell culture and medium
- introduce codon-optimized nucleic acid
- provide codon optimization options
- define decoy receptor
- define detectable label
- describe examples of detectable labels
- describe cleavable sequences for linking detectable labels
- define eukaryotic cell
- describe examples of eukaryotic cells
- define extracellular domain
- describe FGFR3-related skeletal diseases
- describe examples of FGFR3-related skeletal dysplasias
- define Fibroblast Growth Factor
- describe examples of Fibroblast Growth Factors
- define Fibroblast Growth Factor Receptor 3
- describe structure of FGFR3 receptor
- describe mutations in FGFR3 gene
- define fragment of a polypeptide or nucleic acid molecule
- describe examples of fragment lengths
- define FGFR3 polypeptide fragment
- define fusion protein
- define idiopathic skeletal growth retardation disorder
- define monitoring
- define nucleic acid
- define peptide linker
- define pharmaceutically acceptable
- define polypeptide
- describe chemical modifications of polypeptides
- define prevent
- describe FGFR3 polypeptide fragments with varying sequence identities
- describe specific FGFR3 polypeptide fragments
- exclude sFGFR3_Dell from the scope of the invention
- describe fusion protein generation
- describe nucleic acid synthesis
- define prokaryotic cell
- define skeletal growth retardation disorder
- define soluble protein or polypeptide
- define soluble FGFR3 polypeptide
- define specifically binds
- define subject or patient
- define treat, treating, or treatment
- describe symptoms of achondroplasia
- define variant with respect to polypeptides
- define variant with respect to nucleic acids
- describe sequence identity of variant polypeptides
- describe sequence identity of variant nucleic acids
- define vector
- describe types of vectors
- describe vector technologies
- provide references for vector technologies
- conclude definitions section

## DETAILED DESCRIPTION OF THE INVENTION

- introduce soluble FGFR3 polypeptide variants for treating skeletal growth retardation disorders
- describe therapeutic benefit of sFGFR3_Del4 construct in treating achondroplasia
- provide fusion proteins comprising smaller functional portions of sFGFR3 and human hyaluronan and proteoglycan link protein 1 (HPL

### Fibroblast Growth Factor Receptor 3

- define FGFR3 polypeptides and nucleic acids encoding them
- describe FGFR3 polypeptides that bind fibroblast growth factors (FGFs)
- provide examples of FGFR3 polypeptides and their corresponding nucleic acids
- describe naturally occurring isoforms of FGFR3
- provide accession numbers for FGFR3 transcript variants
- define FGFR3 polypeptides with at least 50% amino acid sequence identity
- describe fragments of FGFR3 amino acid sequences
- provide examples of FGFR3 polypeptides with deletions
- describe sFGFR3 polypeptides that bind one or more FGFs
- provide nucleic acids encoding sFGFR3 polypeptides
- describe sFGFR3 polypeptides with N-terminal signal peptide sequences
- provide examples of signal peptide sequences
- describe sFGFR3 polypeptides with deletions of N-terminal amino acids
- provide computer algorithms for predicting signal sequence cleavage sites

### Methods of Treatment

- describe treatment of skeletal growth retardation disorders
- introduce sFGFR3 polypeptide administration
- specify patient population
- outline treatment timing
- describe treatment outcome
- list treatable skeletal growth retardation disorders
- detail symptoms of skeletal growth retardation disorders
- describe administration of sFGFR3 polypeptide or fusion polypeptide
- specify FGFR3-related skeletal diseases
- describe treatment of achondroplasia
- outline symptoms of achondroplasia
- describe monitoring of symptoms
- specify measurement of body weight and skull size
- detail methods of measurement

### Pharmaceutical Compositions and Formulations

- introduce pharmaceutical compositions
- describe administration methods
- list routes of administration
- describe dosage forms
- introduce dosage section
- describe factors affecting dosage
- provide dosage ranges
- describe dosing regimens
- introduce carriers/vehicles section
- describe aqueous and non-aqueous solvents
- list examples of carriers
- describe pharmaceutical acceptable salts
- introduce formulation preparation
- describe sterile injectable solutions
- describe dispersions
- introduce gene therapy section
- describe viral and non-viral vector systems
- list examples of viral vectors
- describe promoters and expression regulatory signals

## EXAMPLES

### Example 1

- describe decoy design and testing procedures
- detail cloning and protein production system
- outline FGF binding assay
- outline aggrecan binding assay
- describe efficacy study in mice and evaluation of velocity of growth
- detail PK/PD analysis
- describe statistical analysis
- summarize results

### Example 2

- summarize in vitro testing of deletion variants

### Example 3

- summarize in vitro testing of Del4 deletion variant
- describe therapeutic efficacy evaluation in transgenic Fgfr3ach/+ mice

### Example 4

- summarize in vitro testing of Del4 deletion variant with LK1-LK2

### Example 5

- summarize in vivo testing of Del4 deletion variant with LK1-LK2
- describe therapeutic efficacy evaluation in Fgfr3ach/+ mice

### Conclusion

- summarize study results and implications

### Example 6

- describe decoy design and purification of sFGFR3 polypeptides and fusion polypeptides
- detail transient transfection and stable cell line generation
- outline purification process using cross-flow filtration and chromatography

### Example 7

- demonstrate role of signal sequence in sFGFR3 polypeptides and fusion polypeptides

### Example 8

- perform biodistribution treatment
- determine biodistribution of sFGFR3_Del1 and sFGFR3_Del4-LK1-LK2
- analyze effect on growth plate thickness
- analyze effect on hypertrophic chondrocyte zone
- perform skull measurements
- perform x-ray radiography
- analyze results for wild-type mice
- analyze results for Fgfr3ach/+ mice
- compare results for sFGFR3_Del1 and sFGFR3_Del4-LK1-LK2
- discuss implications of results

